Renalytix PLC
LSE:RENX
Renalytix PLC
LSE:RENX
Price:
23 GBX
-6.12%
Updated:
Apr 29, 2024
Section:
Relative Value
The Relative Value of one
RENX
stock under the Base Case scenario is
33.28
GBX.
Compared to the current market price of 23 GBX,
Renalytix PLC
is
Undervalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RENX
Relative Value
Base Case
33.28
GBX
Undervaluation 31%
Valuation Multiples
Multiples Across Competitors
RENX Competitors Multiples
Renalytix PLC Competitors
Renalytix PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
29.7m GBP | 10.9 | -0.8 | 46.1 | 43.4 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
32.4B USD | 13.7 | 61.6 | 61.4 | 66.1 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 4.8 | 47.3 | 19.6 | 38.6 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.6 | -116.8 | 16.5 | 111.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1.3T JPY | 5.4 | 27.5 | 14.6 | 16.4 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
11.7B AUD | 78.1 | 163.9 | 112.7 | 112.7 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
7B USD | 11.2 | -331.8 | -175.3 | -162.9 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 9.5 | 32.2 | 21.5 | 22.9 | |
| SE |
|
Sectra AB
STO:SECT B
|
42B SEK | 25.7 | 99.1 | -66.2 | -66.2 | |
| US |
|
Evolent Health Inc
NYSE:EVH
|
3.1B USD | 1.6 | -22.1 | 26.1 | 277.7 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.8B USD | 3.8 | -319.5 | 34.1 | -111.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
